Allan I. Levey

Mapping cross-domain drivers of Alzheimer's disease risk through integrated network analysis

The paper identifies cross-domain drivers of Alzheimer's disease risk by integrating network analysis across biological domains.

Integrated phenotypic and proteomic screening identifies top-tier Alzheimer's disease therapeutic targets

The paper identifies five therapeutic targets for Alzheimer's disease by integrating phenotypic and proteomic screening in murine microglial cells.

Proteomic Subtyping of Alzheimer's Disease CSF links Blood-Brain Barrier Dysfunction to Reduced levels of Tau and Synaptic Biomarkers

The paper identifies six CSF proteomic subtypes in Alzheimer's disease, linking BBB dysfunction to reduced tau and synaptic biomarkers, particularly in African Americans and men.

Multimodal Fusion Analysis of Florbetapir PET and Multiscale Functional Network Connectivity in Alzheimer's Disease

This study integrates Florbetapir PET and functional network connectivity to identify disease progression markers and genetic risk associations in Alzheimer's disease.

Kat5 cKO Biological Domain Signatures Align with Human Alzheimer Disease

The paper compares the transcriptome of Kat5 knockout mice to AD datasets, finding similar gene expression patterns and showing KAT5 localization in AD neurons.

Multiplex Proteomics of Lewy Body Dementia Reveals Cerebrospinal Fluid Biomarkers of Clinical and Neuropathological Heterogeneity

This study uses multiplex proteomics to identify CSF biomarkers of clinical and neuropathological heterogeneity in Lewy body dementia.

Molecular Subtyping Based on Hippocampal Cryptic Exon Burden Reveals Proteome-wide Changes Associated with TDP-43 Pathology across the Spectrum of LATE and Alzheimer's Disease

This study identifies molecular subtypes based on cryptic exon burden in hippocampal tissue, revealing proteomic changes linked to TDP-43 pathology in LATE and Alzheimer's disease.

Network Analysis of the Cerebrospinal Fluid Proteome Reveals Shared and Unique Differences Between Sporadic and Familial Forms of Amyotrophic Lateral Sclerosis

The paper identifies proteomic differences in cerebrospinal fluid between sporadic and familial ALS subtypes using network analysis and validates biomarkers across neurodegenerative diseases.

Mapping Amyloid Networks in Alzheimer's Disease: A High-Order ICA Approach to Gray and White Matter Pathology

This study uses high-order ICA on PET scans to identify amyloid-beta networks in Alzheimer's Disease, revealing distinct gray and white matter patterns associated with cognitive impairment.

Large- Scale Deep Proteomic Analysis in Alzheimer's Disease Brain Regions Across Race and Ethnicity

The paper performs large-scale proteomic analysis of Alzheimer's disease brain regions across different racial and ethnic groups, identifying AD-related protein changes and APOE4 concordance with genotype.

Systems genetic dissection of Alzheimer's disease brain gene expression networks

This study uses a cross-species approach to identify gene expression networks linked to Alzheimer's disease pathology and neurodegeneration.

Bridging the Gap: Multi-Omics Profiling of Brain Tissue in Alzheimer's Disease and Older Controls in Multi-Ethnic Populations

This paper presents a multi-omics dataset from multi-ethnic Alzheimer's disease brain donors, including transcriptome, genome, and proteome data, to improve precision medicine for underrepresented populations.

Development of a Time-Resolved Fluorescence Resonance Energy Transfer ultra-high throughput screening assay for targeting SYK and FCER1G interaction

This paper develops a time-resolved fluorescence resonance energy transfer (TR-FRET) assay for screening small molecule inhibitors targeting the SYK and FCER1G interaction, identifying hematoxylin as a hit.

Network Proteomics of the Lewy Body Dementia Brain Reveals Presynaptic Signatures Distinct from Alzheimer's Disease

This study identifies distinct presynaptic protein networks in Lewy body dementia that differ from Alzheimer's disease using network proteomics.

Aβ Amyloid Scaffolds the Accumulation of Matrisome and Additional Proteins in Alzheimer's Disease

The paper identifies a conserved Aβ amyloid 'responsome' in human and mouse AD brains, showing how amyloid scaffolds proteins involved in disease pathology.

Multiomic Evidence for a Unified Model of Alzheimer's Disease Etiology Linking Microglial Flux Capacity and Astrocyte-Neuron Metabolic Breakdown

An interim exploratory biomarker analysis of a Phase 2 clinical trial to assess the impact of CT1812 in Alzheimers disease

This paper reports exploratory CSF proteomics data from a Phase 2 trial of CT1812 in Alzheimer's disease, identifying pharmacodynamic biomarkers and mechanistic insights.

Global analysis of the heparin-enriched plasma proteome captures matrisome-associated proteins in Alzheimer's disease

The paper uses heparin affinity chromatography to enrich plasma proteomes in Alzheimer's disease, identifying matrisome-associated proteins correlated with AD biomarkers.

Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer's disease.

This study identifies MSN and CD44 as potential therapeutic targets for Alzheimer's disease by developing inhibitors of their interaction through structural and chemical screening.

Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease

The paper compares proteomic profiles of cerebrospinal fluid from African Americans and Caucasians with and without Alzheimer's disease to identify shared and divergent biomarkers.

Multi-Platform Proteomic Analysis of Alzheimer's Disease Cerebrospinal Fluid and Plasma Reveals Network Biomarkers Associated with Proteostasis and the Matrisome

The paper uses multi-platform proteomic analysis of CSF and plasma from Alzheimer's patients to identify biomarkers related to proteostasis and the matrisome.

Unbiased Classification of the Human Brain Proteome Resolves Distinct Clinical and Pathophysiological Subtypes of Cognitive Impairment

The paper uses proteomic profiling to classify cognitive impairment subtypes in human brain tissues, identifying distinct molecular patterns associated with different clinical outcomes.

The landscape of metabolic brain alterations in Alzheimer's disease

This study identifies widespread metabolic dysregulation in Alzheimer's disease brain tissue, linking it to tau pathology and highlighting potential pathomechanisms.

Cell type-specific biotin labeling in vivo resolves regional neuronal proteomic differences in mouse brain

Large-Scale Deep Multi-Layer Analysis of Alzheimer's Disease Brain Reveals Strong Proteomic Disease-Related Changes Not Observed at the RNA Level

The paper analyzes proteomic data from Alzheimer's disease brains, revealing disease-related changes not seen at the RNA level and identifying potential therapeutic targets.

Microglial ERK signaling is a critical regulator of pro-inflammatory immune responses in Alzheimer’s disease

This study identifies ERK phosphorylation in microglia as a critical regulator of pro-inflammatory responses in Alzheimer’s disease using pre-clinical models and human proteomic data.

Genetic control of the human brain proteome

The paper identifies pQTLs for brain proteins and finds they differ from eQTLs, suggesting distinct genetic control of mRNA and protein abundance.

TBK1 interacts with tau and enhances neurodegeneration in tauopathy

This study identifies TBK1 as a tau-interacting kinase that enhances neurodegeneration in tauopathies through increased tau phosphorylation.

Integrated Proteomics Reveals Brain-Based Cerebrospinal Fluid Biomarkers in Asymptomatic and Symptomatic Alzheimer’s Disease

The paper identifies brain-linked CSF biomarkers in Alzheimer’s disease using proteomics, revealing altered levels in both brain and CSF across different disease stages.

Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer's disease

The paper quantitatively analyzes the human brain proteome and phosphoproteome in Alzheimer's disease across different stages using TMT labeling and mass spectrometry.